drugset
drugset / Trial / NCT02820155

Phase I Single and Multiple Escalating Dose Study of RGN1016 in Healthy Male Subjects

NCT02820155 ↗

Phase 1 Unknown 80 enrolled National Taiwan University Hospital National Taiwan University · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a double-blind, randomized, placebo-controlled, dose-escalating, single dose and multiple dose study.

Timeline

Start
2016-06
Primary completion
2017-02
Completion
2017-02

Drugs

EvaluationDrugModalityDoseRoute
Subject RGN1016 Unknown 50 mg Oral
Subject RGN1016 Unknown 100 mg Oral
Subject RGN1016 Unknown 200 mg Oral
Subject RGN1016 Unknown 400 mg Oral
Subject RGN1016 Unknown 800 mg Oral

Indications

No indication recorded.